Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | FNTA | P49354 | 3/20 | 0.52 |
| ▸ | FNTB | P49356 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24209232 | 0.93 | CA12 (0.59) | CA12CA1CA2CA9CA14 | |
| SCHEMBL28533415 | 0.89 | CA1 (0.59) | CA12CA1CA2CA9CA14 | |
| SCHEMBL10048262 | 0.86 | NAMPT (0.58) | CA12CA1CA2CA9CA14 | |
| SCHEMBL12240121 | 0.85 | NAMPT (0.56) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1393864 | 0.85 | CA12 (0.55) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1393863 | 0.85 | CA12 (0.55) | CA12CA1CA2CA9CA14 | |
| SCHEMBL12240119 | 0.85 | CA2 (0.59) | CA12CA1CA2CA9CA14 | |
| SCHEMBL18364959 | 0.82 | CA12 (0.65) | CA12CA1CA2CA9CA14 | |
| SCHEMBL14297345 | 0.82 | CA12 (0.65) | CA12CA1CA2CA9CA14 | |
| SCHEMBL237683 | 0.82 | GAA (0.63) | CA12CA1CA9GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112538058-B | Preparation method of oxazole-containing cyclic sulfone compound | 温州大学新材料与产业技术研究院 | 2022-05-27 | — | — | CN | claimed |
| EP-3325465-B1 | PESTICIDALLY ACTIVE PYRAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2022-05-18 | — | — | EP | claimed |
| CN-112538058-A | Preparation method of oxazole-containing cyclic sulfone compound | 温州大学新材料与产业技术研究院 | 2021-03-23 | — | — | CN | claimed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | claimed |
| EP-0922050-B1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2003-07-30 | — | — | EP | claimed |
| EP-0181152-B1 | PIPERAZINE COMPOUND AS PAF-ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-13 | — | — | EP | claimed |
| US-12628827-B2 | Isoxazoline compounds and their use as pest control agents | PI INDUSTRIES LIMITED (IN) | 2026-05-19 | — | — | US | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| EP-4486452-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LASSS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-01-08 | — | — | EP | disclosed |
| CN-119161324-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-1948310-A | 3 position substituted mesoazalene compounds and high efficiency synthesis method | SHANGHAI INST ORGANIC CHEM (CN) | 2007-04-18 | — | — | CN | disclosed |
| CN-1747950-A | 2- (1H-indazol-6-ylamino) -benzamide compounds as protein kinase inhibitors for the treatment of ocular diseases | PFIZER (US) | 2006-03-15 | — | — | CN | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| US-6251827-B1 | MIXTURE OF PLANT SAFENING AGENT AND ONE OR MORE PESTICIDES | HOECHST SCHERING AGREVO GMBH (DE) | 2001-06-26 | — | — | US | disclosed |
| EP-0339976-B1 | Anti-tumour agents | ICI PLC (GB) | 1994-02-02 | — | — | EP | disclosed |
| US-4889946-A | Phenoxybenzoic acid compounds and herbicidal and plant growth regulant compositions | BAYER AKTIENGESELLSCHAFT (DE) | 1989-12-26 | — | — | US | disclosed |
| EP-0339976-A1 | Anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12628827-B2 | Isoxazoline compounds and their use as pest control agents | HCN1, CBR3, SCN1B | CA12 2274/4885CA1 1154/4885CA2 558/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | CA12 4071/4885CA1 3598/4885CA2 3019/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | CA12 4537/4885CA1 3701/4885CA2 1982/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | CA12 4071/4885CA1 3598/4885CA2 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.